Clinical Trials Logo

ER+ HER2- Advanced Breast Cancer clinical trials

View clinical trials related to ER+ HER2- Advanced Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06188520 Recruiting - Clinical trials for ER+ HER2- Advanced Breast Cancer

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

CYCAD-1
Start date: December 5, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

NCT ID: NCT04541433 Active, not recruiting - Clinical trials for ER+ HER2- Advanced Breast Cancer

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Start date: September 29, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD9833 in Japanese women with endocrineresistant ER+ HER2- breast cancer that is not amenable to treatment with curative intent. This study consists of 2 cohorts, Cohort1 and Cohort2. In cohort 1 (for tolerability evaluation), a minimum of 3, or up to 6, evaluable Japanese patients with ER+ HER2- breast cancer will be enrolled. In cohort 2 (for exploratory research), at least 6 to maximum 12 evaluable Japanese patients with ER+ HER2- breast cancer will be enrolled.

NCT ID: NCT03616587 Active, not recruiting - Clinical trials for ER+ HER2- Advanced Breast Cancer

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

SERENA-1
Start date: October 11, 2018
Phase: Phase 1
Study type: Interventional

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)

NCT ID: NCT03596658 Terminated - Clinical trials for ER+ HER2- Advanced Breast Cancer

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Start date: July 25, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1 open label multicentre study of SHR9549 administered orally in patients with advanced estrogen receptor (ER) positive human epidermal receptor 2 (HER2) negative breast cancer. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. The study will determine the maximum tolerated dose(MTD). In addition, expansion cohort(s) at potential therapeutic dose(s) in patients will be enrolled to further determine the safety, tolerability, pharmacokinetics and biological activity of SHR9549.

NCT ID: NCT02248090 Completed - Clinical trials for ER+ HER2- Advanced Breast Cancer

AZD9496 First Time in Patients Ascending Dose Study

Start date: October 22, 2014
Phase: Phase 1
Study type: Interventional

This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. The study will determine the maximum tolerated dose. In addition, expansion cohort(s) at potential therapeutic dose(s) in patients with or without ESR1 mutations will be enrolled to further determine the safety, tolerability, pharmacokinetics and biological activity of AZD9496